CEP170B

Across TCGA pan-cancer cohorts, CEP170B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEP170B data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher CEP170B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEP170B expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

TGCT, UCEC, and LUAD are the cancer types where CEP170B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	DFS	Median	All	0.067	0.802	.001	6	view →
UCEC	DFS	Median	All	0.975	0.828	.017	6	view →
LUAD	OS	Median	All	0.340	0.700	.015	6	view →
COAD	DFS	Median	All	1.000	0.469	.038	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	OS	Median	IV	0.202	0.484	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEP170B–TGCT (DFS)

Open the TGCT breakdown →